Chemosensitivity of glioblastoma cells during treatment with the organo-tin compound triethyltin(IV)lupinylsulfide hydrochloride

Journal of Neuro-Oncology

Volumn 60, Issue 2, 2002, Pages 109-116

  Barbieri, F ^a   Sparatore, F ^b   Bonavia, R ^a   Bruzzo, C ^a   Schettini, G ^a   Alama, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Cell morphology; Cytotoxicity; Glioblastoma cell lines; In vitro; Organo tin compound

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; IST FS 29; TIN DERIVATIVE; TRIETHYLTIN LUPINYLSULFIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CELL COUNT; CELL DAMAGE; CELL DEATH; CELL STRUCTURE; CELL VACUOLE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; DRUG EFFECT; DRUG EXPOSURE; DRUG WITHDRAWAL; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIPOPHILICITY; MICROSCOPY; NECROSIS;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CALCIUM; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HUMANS; SIGNAL TRANSDUCTION; TRIETHYLTIN COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0036843416     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020630214549     Document Type: Article

References (22)

1. Prados MD, Levin V: Biology and treatment of malignant glioma. Semin Oncol 27(3): 1-10, 2000
2. Mohri M, Nitta H, Yamashita J: Expression of multidrug resistance-associated protein (MRP) in human gliomas. J Neuro-Oncol 49: 105-115, 2000
3. Saxena A, Shriml LM, Dean M, Unnisa Ali I: Comparative molecular genetic profiles of anaplastic astrocytomas/glioblastomas multiforme and their subsequent recurrences. Oncogene 18: 1385-1390, 1999
4. Jennings MT, Iyengar S: Pharmacotherapy of malignant astrocytomas of children and adults: current strategies and future trends. CNS Drugs 15(9): 719-743, 2001
5. Respondek J, Engel J: Organo-metallics in medicine. Drugs Future 21(4): 391-408, 1996
6. Penninks AH, Bol-Schoenmakers M, Seinen W: Cellular interactions of organo-tin compounds in relation to their antitumor activity. In: Gielen M (ed) Tin-based Antitumor Drugs. Springer-Verlag, Berlin, Heidelberg, 1990, pp 169-190
7. Cardarelli NF, Quitter BM, Allen A, Dobbins E, Libby EP, Hager P, Sherman LR: Organo-tin implications in anticarcinogenesis. Background and thymus involvement. Aust J Exp Biol Med Sci 62: 199-208, 1984
8. Cagnoli M, Alama A, Barbieri F, Novelli F, Bruzzo C, Sparatore F: Synthesis and biological activity of gold and tin compounds in ovarian cancer cells. Anticancer Drugs 9: 603-610, 1998
9. Barbieri F, Viale M, Sparatore F, Favre A, Cagnoli M, Bruzzo C, Novelli F, Alama A: Cytotoxicity in vitro and preliminary antitumor activity in vivo of a novel organo-tin compound. Anticancer Res 20: 977-980, 2000
10. Karpiac VC, Eyer CL: Differential gliotoxicity of organo-tins. Cell Biol Toxicol 15(4): 261-268, 1999
11. Aschner M, Aschner JL: Cellular and molecular effects of trimethylin and triethylin: relevance to organo-tin neurotoxicity. Neurosci Biobehav Rev 16: 427-435, 1992
12. 2+ signaling and potentiates norepinephrine release in PC12 cells. Toxicol Appl Pharmacol 140: 289-295, 1996
13. Novelli F, Sparatore F: Thiolupinine and some derivatives of pharmacological interest. I1 Farmaco 48: 1021-1049, 1993
14. Meucci O, Scorziello A, Avallone A, Florio T, Schettini G: α1B, but not α1A, adrenoreceptor activates calcium influx through the stimulation of a tyrosine kinase/phosphotyrosine phosphatase pathway, following noradrenaline-induced emptying of IP3 sensitive calcium stores, in PCC13 rat thyroid cell line. Biochem Biophys Res Com 209(2): 630-638, 1995
15. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260(6): 3440-3450, 1985
16. Terwogt JMM, Schellens JHM, ten Bokkel Huinink WW, Beijnen JH: Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat Rev 25: 83-101, 1999
17. Winship KA: Toxicity of tin and its compounds. Adverse Drug React Acute Poisoning Rev 7(1): 19-38, 1988
18. Barbieri F, Viale M, Sparatore F, Schettini G, Favre A, Bruzzo C, Novelli F, Alama A: Antitumor activity of new orally active organo-tin compound: a preliminary study in murine tumor models. Anticancer Drugs, 13(6): 599-604, 2002
19. Yallapragada PR, Vig PJS, Kodavanti PRS, Desaiah D: In vivo effects of triorgano-tins on calmodulin activity in rat brain. J Toxicol Env Health 34: 229-237, 1991
20. Barbieri F, Sparatore F, Cagnoli M, Bruzzo C, Novelli F, Alama A: Antiproliferative activity and interactions with cell-cycle related proteins of the organo-tin compound triethyltin(IV)lupinylsulfide hydrochloride. Chem Biol Interact 134: 27-39, 2001
21. Wolff JEA, Trilling T, Molenkamp G, Egeler RM, Jurgens H: Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 125: 481-486, 1999
22. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat Rev 23: 35-61, 1997